After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treat...
Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational drug...